Statins for kidney disease patients: Protection for the heart but no effects on kidneys

May 1, 2014

Lowering LDL cholesterol through statin-based treatment did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The results indicate that while LDL cholesterol-lowering therapy is safe in kidney disease patients and can reduce their risk of heart disease and stroke, it does not protect their kidney health as well.

Research has shown that lowering LDL cholesterol with statins can reduce patients' risk of experiencing heart attacks and strokes, but it's not clear whether it can also reduce the risk of , which requires dialysis or , in these patients.

To investigate, researchers conducted the Study of Heart and Renal Protection (SHARP), which included 6,245 nondialysis patients who were randomized to receive a placebo or cholesterol-lowering treatment with simvastatin (a statin) plus ezetimibe (a drug that inhibits the intestinal absorption of cholesterol).

Among the major findings after 5 years of follow-up:

  • Simvastatin plus ezetimibe lowered LDL cholesterol by an average of approximately 1 mmol/L (39 mg/dL) compared with placebo.
  • Simvastatin plus ezetimibe did not significantly reduce the need for dialysis or transplantation (33.9% cases vs 34.6% cases in the placebo group).
  • Treatment had no effect on the speed at which kidney function declined over time.

"The SHARP trial was the largest ever randomized trial in chronic kidney disease and previously showed that simvastatin plus ezetimibe did reduce the risk of heart attack, stroke, vascular stenting, or bypass surgery, but it did not affect the risk of end-stage renal disease," said first author Richard Haynes, MRCP (University of Oxford, UK). "Statins had no effect—neither good nor bad—on kidney function."

Explore further: Evolocumab safely drops LDL cholesterol well below statin-only baseline

More information: The article, entitled "Effects of Lowering LDL Cholesterol on Progression of Kidney Disease," will appear online at jasn.asnjournals.org/ on May 1, 2014.

Related Stories

Evolocumab safely drops LDL cholesterol well below statin-only baseline

March 31, 2014
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 ...

LDL cholesterol is a poor marker of heart health in patients with kidney disease

May 16, 2013
LDL cholesterol is not a useful marker of heart disease risk in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The finding suggests ...

Significantly improved chance of heart attack survival with high-potency statin treatment

February 20, 2014
(Medical Xpress)—A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking ...

Heart drug 'safe for kidney patients'

June 13, 2011
(Medical Xpress) -- The full results of a trial show that people with chronic kidney disease can reduce their heart risk by taking a combination drug that lowers levels of ‘bad’ cholesterol.

Poor quality of life may contribute to kidney disease patients' health problems

April 3, 2014
Kidney disease patients with poor quality of life are at increased risk of experiencing progression of their disease and of developing heart problems, according to a study appearing in an upcoming issue of the Journal of ...

Recommended for you

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

August 15, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego and the University of Colorado Anschutz Medical Campus have found that compounds produced by the creosote bush, a ...

New malaria analysis method reveals disease severity in minutes

August 11, 2017
Left untreated, malaria can progress from being mild to severe—and potentially fatal—in 24 hours. So researchers at the University of British Columbia developed a method to quickly and sensitively assess the progression ...

Drug trial shows promise for deadly neurological disorder

August 10, 2017
Results of a small clinical trial show promise for treating a rare neurodegenerative condition that typically kills those afflicted before they reach age 20. The disease, called Niemann-Pick type C (NPC), causes cholesterol ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.